CYTOO Email Format

Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees

CYTOO is a preclinical stage biotechnology company focused on muscular and neuromuscular disorders. It partners with pharmaceutical and biotech companies, deploying its patient-derived muscle drug discovery engine while also developing its own drug candidates. Its core asset is a mature human in vitro muscle model called MyoScreen, derived from primary human samples including both healthy and diseased myoblasts, used to generate new chemical entities for a range of pathological conditions, including rare and chronic diseases. Based in Grenoble, France, the company operates with a small-to-mid-sized team within the biotechnology research sector. Notable collaborations include Pfizer in 2018 to gain insights into Duchenne muscular dystrophy and a 2020 partnership with AskBio to develop an AAV-based screening platform from patient cells, alongside the 2015 launch of MyoScreen.

Sign up for free to view info

Company overview Employee directory